For years, sleep disturbances in patients with neurodegenerative diseases were treated as secondary symptoms, unfortunate but downstream consequences of a dying brain. A growing body of evidence has collapsed that assumption. A new synthesis published in Med Clin North America by Desai and colleagues argues that sleep disorders and neurodegeneration are fundamentally bidirectional: each condition worsens the other, and treating one can alter the trajectory of the other.
The review covers Alzheimer disease, Parkinson disease, vascular dementia, and amyotrophic lateral sclerosis (ALS) and makes a pointed clinical argument: sleep screening should become a standard part of the diagnostic workup for any suspected neurodegenerative condition. The authors note that sleep disorders are a common factor across all major neurodegenerative diseases, yet they remain underrecognized and undertreated in neurologic practice.
Sleep as a Window: REM Sleep Behavior Disorder
The clearest example of sleep as a diagnostic window comes from rapid eye movement sleep behavior disorder, or RBD. In RBD, the normal muscle atonia of REM sleep is lost. Patients physically act out their dreams, sometimes violently, shouting, thrashing, or injuring bed partners. What makes RBD clinically critical is its predictive power.
Longitudinal studies have shown that 60 to 90 percent of patients with isolated RBD will convert to a synucleinopathy within 10 to 15 years, usually Parkinson disease or dementia with Lewy bodies. Autopsy and imaging studies reveal that these patients already harbor alpha-synuclein pathology in the brainstem nuclei that regulate REM sleep, years before any motor or cognitive symptom appears. RBD is arguably the most specific clinical biomarker available for prodromal synucleinopathy. The review emphasizes that new-onset RBD should trigger a neurology referral and longitudinal follow-up.
This pattern is not limited to the synucleinopathies. In Alzheimer disease, changes in sleep architecture including reduced slow-wave sleep and alterations in sleep spindle density on electroencephalography can be detected in cognitively healthy older adults who have elevated amyloid burden on PET imaging. Sleep may provide the earliest window into neurodegenerative pathology across multiple disease types.
Sleep as a Mechanism: Glymphatic Clearance
Sleep is not merely a passive marker of neurodegeneration. It is an active participant in the underlying pathology. The glymphatic system, the brain’s waste clearance network, is most active during deep non-REM sleep. During slow-wave sleep, cerebrospinal fluid flows through brain tissue, flushing out metabolic waste products including amyloid-beta and tau, the proteins that form the hallmark plaques and tangles of Alzheimer disease.
When sleep is fragmented or insufficient, this clearance is impaired. Positron emission tomography studies have shown that even a single night of sleep deprivation can measurably increase amyloid-beta burden in the human brain. Over time, a self-reinforcing cycle develops: amyloid plaques disrupt sleep architecture, and disrupted sleep accelerates plaque formation. Circadian clock disruption also plays a role in other neurodegenerative diseases. In Huntington disease, for example, dysregulation of core clock genes such as BMAL1 and PER2 leads to fragmented sleep-wake cycles that precede clinical onset.
In ALS, the mechanism is different but equally destructive. Diaphragmatic weakness causes nocturnal hypoventilation, leading to frequent arousals and oxygen desaturations long before daytime respiratory failure becomes apparent. Patients show reduced REM sleep, increased fragmentation, and loss of sleep spindles. Noninvasive ventilation improves sleep quality and may extend survival.
Clinical Implications
The review’s practical argument is straightforward. Sleep disorders are treatable, and treating them in the context of neurodegeneration may slow symptomatic progression, improve quality of life, and reduce caregiver burden.
The authors recommend structured sleep screening in all patients with known or suspected neurodegenerative disease. Simple instruments such as the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, and the RBD Screening Questionnaire can be administered in a primary care or neurology clinic in minutes. Abnormal findings should prompt formal polysomnography to differentiate among the overlapping sleep disorders that affect this population: insomnia, circadian rhythm disruption, sleep-disordered breathing, RBD, and periodic limb movement disorder.
Management should be tailored to the specific sleep disorder and the underlying neurodegenerative condition. For Alzheimer patients, cognitive behavioral therapy for insomnia, timed light exposure, and melatonin (with avoidance of anticholinergic sedatives such as diphenhydramine) can improve sleep continuity. For Parkinson patients, melatonin or low-dose clonazepam can reduce RBD-related injury risk, while continuous positive airway pressure for comorbid obstructive sleep apnea may improve both daytime sleepiness and motor function.
The review also flags risks. Benzodiazepines and Z-drugs, frequently prescribed for insomnia in older adults, carry amplified risks of falls, cognitive worsening, and dependence in this population. Safer alternatives such as melatonin and behavioral interventions should be prioritized.
Limitations
As a narrative review, this paper synthesizes existing literature rather than presenting new data. The bidirectional model is strongly supported by epidemiologic and mechanistic evidence, but causality remains difficult to prove in controlled trials. Sleep interventions in neurodegenerative disease are typically multimodal, and the disease course is long. Much of the evidence comes from Alzheimer and Parkinson disease, with comparatively less data on the sleep profiles of vascular dementia, frontotemporal dementia, and ALS. These gaps highlight the need for prospective studies that test whether sleep-targeted interventions can alter disease progression.
Source
Desai KM, Thakkar MD, Somaiya TS, Thomas DC. Neurodegenerative Diseases and Sleep Disorders: The Bidirectional Relationship. Med Clin North Am. 2026 Sep;110(5):889-905. DOI: 10.1016/j.mcna.2025.12.001. PMID: 42498430.